Swiss Re AG
DUS:SR9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Swiss Re AG
DUS:SR9
|
CH |
|
P
|
Pfizer Inc
XHAM:PFE
|
US |
|
B
|
Bank of Montreal
XMUN:BZZ
|
CA |
|
D
|
Deutsche Telekom AG
XMUN:DTE
|
DE |
|
B
|
Berkeley Group Holdings PLC
OTC:BKGFF
|
UK |
|
AGL Energy Ltd
ASX:AGL
|
AU |
|
R
|
Relx PLC
XMUN:RDEB
|
UK |
|
I
|
International Flavors & Fragrances Inc
F:IFF
|
US |
|
P
|
Paychex Inc
SWB:PCX
|
US |
|
M
|
Microchip Technology Inc
DUS:MCP
|
US |
|
B
|
Biogen Inc
XMUN:IDP
|
US |
|
P
|
Parker-Hannifin Corp
F:PAR
|
US |
|
T
|
Truist Financial Corp
XMUN:BBK
|
US |
|
T
|
Targa Resources Corp
F:TAR
|
US |
|
S
|
Standard Bank Group Ltd
XMUN:SKC2
|
ZA |
|
M
|
Mizuho Financial Group Inc
XMUN:MZ8
|
JP |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is SR9's stock price target?
Price Target
132.2
EUR
According to Wall Street analysts, the average 1-year price target for
SR9 is 132.2 EUR with a low forecast of 119.2 EUR and a high forecast of 177.02 EUR.
What is the Revenue forecast for Swiss Re AG?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Revenue has been 2%. The projected CAGR for the next 8 years is 7%.
What is the Net Income forecast for Swiss Re AG?
Projected CAGR
6%
Over the last 13 years, the compound annual growth rate for Net Income has been 1%. The projected CAGR for the next 8 years is 6%.